Lilly's retatrutide shows blood sugar, weight reduction in diabetes trial

March 19, 2026 6:45 AM

Eli Lilly and Company (NYSE: LLY) announced results from a Phase 3 clinical trial showing its investigational drug retatrutide reduced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found